Daniela Maria Allmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniela Maria Allmer has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gere Sunder-Plassmann
Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria
4 shared publications - Alice Schmidt
Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria
3 shared publications Christof Aigner
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
1 shared publication- Christopher Paschen
Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Waehringer Guertel 18-20 1090 Vienna, Austria
1 shared publication - Constantin Gatterer
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication Diego Parada Rodriguez
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 5 (4)
Disappointment and/or a glimmer of hope? - When biochemical efficacy does not translate into (primary) clinical benefit
- 30 October 2026
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 5 (4)
Open AccessDisappointment and/or a glimmer of hope? - When biochemical efficacy does not translate into (primary) clinical benefit
- Open Access
- 20 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2390
Longitudinal Adipokine and Lipid Profiles in Fabry Disease
Background/Objectives: Fabry disease (FD) is a lysosomal storage disorder characterized by progressive renal and cardiac involvement and an increased burden of cardiovascular and cerebrovascular events. While cardiac magnetic resonance imaging (CMR) has significantly advanced structural assessment, circulating biomarkers reflecting disease-related cardiac manifestations remain incompletely understood. We therefore investigated adiponectin and leptin, two adipokines involved in inflammatory, metabolic, and fibrotic pathways, in relation to cardiac involvement and analyzed long-term lipid trajectories in FD. Methods: This longitudinal observational study included 49 patients with FD with 149 study visits. Circulating adiponectin, leptin, NT-proBNP, and conventional lipid parameters were assessed longitudinally and stratified by FD-specific therapy status and sex. Multivariable linear regression was performed to evaluate independent associations with log-transformed NT-proBNP values. Results: Adiponectin was positively associated with NT-proBNP, reflecting cardiac involvement, independent of age, sex, BMI, and eGFR (p < 0.001). Higher adiponectin levels were observed in patients with left ventricular hypertrophy or low T1 and those with fibrosis, detected by CMR (p = 0.009 and p < 0.001, respectively). This association was mainly seen in patients receiving FD-specific therapy, raising the question of whether this reflects underlying organ involvement or treatment effects. Leptin demonstrated weaker, inverse associations. Adiponectin, leptin, Triglycerides, total cholesterol, and HDL- and LDL-cholesterol levels remained stable over long-term follow-up, irrespective of FD-specific therapy or sex. Conclusions: In FD, adiponectin appears to be associated with cardiac involvement, and conventional lipid parameters remained unchanged over time. These findings suggest that alterations in adipokines, rather than progressive dyslipidemia, may reflect disease-related cardiac manifestations.
- 20 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2390
Open AccessLongitudinal Adipokine and Lipid Profiles in Fabry Disease
Background/Objectives: Fabry disease (FD) is a lysosomal storage disorder characterized by progressive renal and cardiac involvement and an increased burden of cardiovascular and cerebrovascular events. While cardiac magnetic resonance imaging (CMR) has significantly advanced structural assessment, circulating biomarkers reflecting disease-related cardiac manifestations remain incompletely understood. We therefore investigated adiponectin and leptin, two adipokines involved in inflammatory, metabolic, and fibrotic pathways, in relation to cardiac involvement and analyzed long-term lipid trajectories in FD. Methods: This longitudinal observational study included 49 patients with FD with 149 study visits. Circulating adiponectin, leptin, NT-proBNP, and conventional lipid parameters were assessed longitudinally and stratified by FD-specific therapy status and sex. Multivariable linear regression was performed to evaluate independent associations with log-transformed NT-proBNP values. Results: Adiponectin was positively associated with NT-proBNP, reflecting cardiac involvement, independent of age, sex, BMI, and eGFR (p < 0.001). Higher adiponectin levels were observed in patients with left ventricular hypertrophy or low T1 and those with fibrosis, detected by CMR (p = 0.009 and p < 0.001, respectively). This association was mainly seen in patients receiving FD-specific therapy, raising the question of whether this reflects underlying organ involvement or treatment effects. Leptin demonstrated weaker, inverse associations. Adiponectin, leptin, Triglycerides, total cholesterol, and HDL- and LDL-cholesterol levels remained stable over long-term follow-up, irrespective of FD-specific therapy or sex. Conclusions: In FD, adiponectin appears to be associated with cardiac involvement, and conventional lipid parameters remained unchanged over time. These findings suggest that alterations in adipokines, rather than progressive dyslipidemia, may reflect disease-related cardiac manifestations.
- 6 October 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 138 (9-10) , 312-314
Nutcracker syndrome in an Alport family: a tricky case
Summary Diagnosing nutcracker syndrome can be challenging, particularly when symptoms are suggestive of more common conditions. In such cases, the syndrome is often not considered as an initial differential diagnosis. We report the case of a 30-year-old woman with a history of microhematuria since childhood as well as previous episodes of macrohematuria, abdominal pain and urinary tract infections. As her mother, sister and other relatives are affected by Alport syndrome and chronic kidney disease, this was primarily suspected to be the cause of the symptoms; however, serum creatinine was within the normal range, albuminuria was absent and repeated genetic testing for the pathogenic COL4A5 variant inherited in her family was negative. Given the persistence of the symptoms, magnetic resonance angiography was performed, revealing findings consistent with symptomatic nutcracker syndrome. The patient declined interventional or surgical treatment. This case illustrates the diagnostic challenge of nutcracker syndrome, particularly when symptoms overlap with more common and reasonable conditions. It underscores the importance of considering vascular causes in patients with unexplained hematuria, even in the context of a family history of Alport syndrome.
- 6 October 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 138 (9-10) , 312-314
Nutcracker syndrome in an Alport family: a tricky case
Summary Diagnosing nutcracker syndrome can be challenging, particularly when symptoms are suggestive of more common conditions. In such cases, the syndrome is often not considered as an initial differential diagnosis. We report the case of a 30-year-old woman with a history of microhematuria since childhood as well as previous episodes of macrohematuria, abdominal pain and urinary tract infections. As her mother, sister and other relatives are affected by Alport syndrome and chronic kidney disease, this was primarily suspected to be the cause of the symptoms; however, serum creatinine was within the normal range, albuminuria was absent and repeated genetic testing for the pathogenic COL4A5 variant inherited in her family was negative. Given the persistence of the symptoms, magnetic resonance angiography was performed, revealing findings consistent with symptomatic nutcracker syndrome. The patient declined interventional or surgical treatment. This case illustrates the diagnostic challenge of nutcracker syndrome, particularly when symptoms overlap with more common and reasonable conditions. It underscores the importance of considering vascular causes in patients with unexplained hematuria, even in the context of a family history of Alport syndrome.
- Open Access
- 7 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1470309
Progression to kidney failure in ADPKD: the PROPKD score underestimates the risk assessed by the Mayo imaging classification
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and fourth leading cause for renal replacement therapy worldwide. Disease progression is tightly linked to genotype, however, factors like genetic modifiers and environmental factors are responsible for a high phenotypic variability within- as well as between families. Individual’s risk of progression to kidney failure is assessed using prediction- or risk-assessment tools such as the predicting renal outcomes in ADPKD score (PROPKD score) and the Mayo Imaging Classification (MIC). The PROPKD score encompasses genetic and phenotypic parameters, while the MIC relies on renal imaging, height, and age of patients. Both methods categorize patients into low-risk, intermediate-risk, and high-risk for progression to kidney failure. In this retrospective, cross-sectional study, we calculated the risk of progression to kidney failure in our population and analyzed the agreement between the methods in three separate models with alternating stratification of MIC risk categories. We found a mismatch for risk assessment between the respective risk categories, indicating that the PROPKD score and MIC should not be used interchangeably. Preferably, the MIC should be used as a base for risk assessment and may be enhanced by genotypic and phenotypic information.
- 7 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1470309
Open AccessProgression to kidney failure in ADPKD: the PROPKD score underestimates the risk assessed by the Mayo imaging classification
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and fourth leading cause for renal replacement therapy worldwide. Disease progression is tightly linked to genotype, however, factors like genetic modifiers and environmental factors are responsible for a high phenotypic variability within- as well as between families. Individual’s risk of progression to kidney failure is assessed using prediction- or risk-assessment tools such as the predicting renal outcomes in ADPKD score (PROPKD score) and the Mayo Imaging Classification (MIC). The PROPKD score encompasses genetic and phenotypic parameters, while the MIC relies on renal imaging, height, and age of patients. Both methods categorize patients into low-risk, intermediate-risk, and high-risk for progression to kidney failure. In this retrospective, cross-sectional study, we calculated the risk of progression to kidney failure in our population and analyzed the agreement between the methods in three separate models with alternating stratification of MIC risk categories. We found a mismatch for risk assessment between the respective risk categories, indicating that the PROPKD score and MIC should not be used interchangeably. Preferably, the MIC should be used as a base for risk assessment and may be enhanced by genotypic and phenotypic information.